Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00232661
Status:
COMPLETED
Last Update Posted:
2010-02-03
First Post:
2005-09-30
Brief Title:
PROACT - Pre-Operative Arimidex Compared To Tamoxifen
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomised Double-blind Study Comparing ARIMIDEX With NOLVADEX as Neo-adjuvant and Adjuvant Treatment in Post-menopausal Women With Large Operable T2 3cm T3 N0-2 M0 or Potentially-operable Locally Advanced T4b N0-2 M0 ER andor PR Breast Cancer
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare tamoxifen versus a newer treatment ARIMIDEX which we already know to be well tolerated The main objectives of this research study are to see whether using these drugs will shrink down tumours before surgery and to see if any shrinkage in the tumour affects the extent of surgery that is required
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| D5395C00039 | None | None | None |